{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:32:20Z","timestamp":1781109140875,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Wuhan Science and Technology Bureau","award":["2023020201020542"],"award-info":[{"award-number":["2023020201020542"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17232-6","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:10:48Z","timestamp":1756354248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Dan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-long","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"17232_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","volume":"40","author":"S Ottaviani","year":"2011","unstructured":"Ottaviani, S., Ayral, X., Dougados, M. & Gossec, L. Pigmented villonodular synovitis: A retrospective single-center study of 122 cases and review of the literature. Semin. Arthritis Rheum. 40, 539\u2013546. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.07.005 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"17232_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40268-020-00314-3","volume":"20","author":"S Monestime","year":"2020","unstructured":"Monestime, S. & Lazaridis, D. Pexidartinib (TURALIO): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor. Drugs R D 20, 189\u2013195. https:\/\/doi.org\/10.1007\/s40268-020-00314-3 (2020).","journal-title":"Drugs R D"},{"key":"17232_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ocl.2005.08.002","volume":"37","author":"O Ofluoglu","year":"2006","unstructured":"Ofluoglu, O. Pigmented villonodular synovitis. Orthop. Clin. N. Am. 37, 23\u201333. https:\/\/doi.org\/10.1016\/j.ocl.2005.08.002 (2006).","journal-title":"Orthop. Clin. N. Am."},{"key":"17232_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60101675","author":"V Dania","year":"2024","unstructured":"Dania, V. et al. Treatment modalities for refractory-recurrent tenosynovial giant cell tumor (TGCT): An update. Medicina https:\/\/doi.org\/10.3390\/medicina60101675 (2024).","journal-title":"Medicina"},{"key":"17232_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.2017.75.8482","volume":"36","author":"MM Gounder","year":"2018","unstructured":"Gounder, M. M., Thomas, D. M. & Tap, W. D. Locally aggressive connective tissue tumors. J. Clin. Oncol. 36, 202\u2013209. https:\/\/doi.org\/10.1200\/JCO.2017.75.8482 (2018).","journal-title":"J. Clin. Oncol."},{"key":"17232_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","volume":"63","author":"EL Staals","year":"2016","unstructured":"Staals, E. L., Ferrari, S., Donati, D. M. & Palmerini, E. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives. Eur. J. Cancer 63, 34\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2016.04.022 (2016).","journal-title":"Eur. J. Cancer"},{"key":"17232_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","volume":"20","author":"MJL Mastboom","year":"2019","unstructured":"Mastboom, M. J. L. et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: An international, retrospective, cohort study. Lancet Oncol. 20, 877\u2013886. https:\/\/doi.org\/10.1016\/S1470-2045(19)30100-7 (2019).","journal-title":"Lancet Oncol."},{"key":"17232_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdn033","volume":"19","author":"JY Blay","year":"2008","unstructured":"Blay, J. Y., El Sayadi, H., Thiesse, P., Garret, J. & Ray-Coquard, I. Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT). Ann. Oncol. 19, 821\u2013822. https:\/\/doi.org\/10.1093\/annonc\/mdn033 (2008).","journal-title":"Ann. Oncol."},{"key":"17232_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2045-3329-3-8","volume":"3","author":"S Stacchiotti","year":"2013","unstructured":"Stacchiotti, S. et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin. Sarcoma Res. 3, 8. https:\/\/doi.org\/10.1186\/2045-3329-3-8 (2013).","journal-title":"Clin. Sarcoma Res."},{"key":"17232_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier, P. A. et al. Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer 118, 1649\u20131655. https:\/\/doi.org\/10.1002\/cncr.26409 (2012).","journal-title":"Cancer"},{"key":"17232_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","volume":"173","author":"G Spierenburg","year":"2022","unstructured":"Spierenburg, G. et al. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT. Eur. J. Cancer 173, 219\u2013228. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.028 (2022).","journal-title":"Eur. J. Cancer"},{"key":"17232_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","volume":"19","author":"H Gelderblom","year":"2018","unstructured":"Gelderblom, H. et al. Nilotinib in locally advanced pigmented villonodular synovitis: A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 19, 639\u2013648. https:\/\/doi.org\/10.1016\/S1470-2045(18)30143-8 (2018).","journal-title":"Lancet Oncol."},{"key":"17232_CR13","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","volume":"79","author":"Y Lamb","year":"2019","unstructured":"Lamb, Y. N. PExidartinib: First approval. Drugs 79, 1805\u20131812. https:\/\/doi.org\/10.1007\/s40265-019-01210-0 (2019).","journal-title":"Drugs"},{"key":"17232_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap, W. D. et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial. Lancet 394, 478\u2013487. https:\/\/doi.org\/10.1016\/S0140-6736(19)30764-0 (2019).","journal-title":"Lancet"},{"key":"17232_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-020-01280-5","volume":"80","author":"YN Lamb","year":"2020","unstructured":"Lamb, Y. N. Correction to: Pexidartinib: First approval. Drugs 80, 447. https:\/\/doi.org\/10.1007\/s40265-020-01280-5 (2020).","journal-title":"Drugs"},{"key":"17232_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"17232_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2446429","author":"WL Xie","year":"2024","unstructured":"Xie, W. L., Li, H. H., Li, D., Li, J. Y. & Deng, A. P. A real-world pharmacovigilance analysis for agalsidase beta: Findings from the FDA adverse event reporting database. Expert Opin. Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2446429 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"17232_CR18","doi-asserted-by":"publisher","first-page":"1382924","DOI":"10.3389\/fphar.2024.1382924","volume":"15","author":"K Chen","year":"2024","unstructured":"Chen, K., Huang, H., Chen, Y. & He, W. Association between atorvastatin and erectile dysfunction: A comprehensive analysis incorporating real-world pharmacovigilance and Mendelian randomization. Front. Pharmacol. 15, 1382924. https:\/\/doi.org\/10.3389\/fphar.2024.1382924 (2024).","journal-title":"Front. Pharmacol."},{"key":"17232_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1517\/14740338.6.4.451","volume":"6","author":"RP van Manen","year":"2007","unstructured":"van Manen, R. P., Fram, D. & DuMouchel, W. Signal detection methodologies to support effective safety management. Expert Opin. Drug Saf. 6, 451\u2013464. https:\/\/doi.org\/10.1517\/14740338.6.4.451 (2007).","journal-title":"Expert Opin. Drug Saf."},{"key":"17232_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","volume":"48","author":"L Huang","year":"2014","unstructured":"Huang, L., Guo, T., Zalkikar, J. N. & Tiwari, R. C. A review of statistical methods for safety surveillance. Ther. Innov. Regul. Sci. 48, 98\u2013108. https:\/\/doi.org\/10.1177\/2168479013514236 (2014).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"17232_CR21","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1002\/onco.13629","volume":"26","author":"JH Lewis","year":"2021","unstructured":"Lewis, J. H. et al. Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors. Oncologist 26, e863\u2013e873. https:\/\/doi.org\/10.1002\/onco.13629 (2021).","journal-title":"Oncologist"},{"key":"17232_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2217\/cer-2020-0253","volume":"10","author":"M Salas","year":"2021","unstructured":"Salas, M. et al. Evaluation of patient\/caregiver and healthcare provider knowledge, attitudes and behavior for safety and use of pexidartinib. J. Comp. Eff. Res. 10, 953\u2013967. https:\/\/doi.org\/10.2217\/cer-2020-0253 (2021).","journal-title":"J. Comp. Eff. Res."},{"key":"17232_CR23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/fon-2021-1475","volume":"18","author":"C Dharmani","year":"2022","unstructured":"Dharmani, C. et al. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: Framework and experience. Future Oncol. 18, 1595\u20131607. https:\/\/doi.org\/10.2217\/fon-2021-1475 (2022).","journal-title":"Future Oncol."},{"key":"17232_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/14737140.2020.1757441","volume":"20","author":"E Palmerini","year":"2020","unstructured":"Palmerini, E., Longhi, A., Donati, D. M. & Staals, E. L. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: Safety and efficacy. Expert Rev. Anticancer Ther. 20, 441\u2013445. https:\/\/doi.org\/10.1080\/14737140.2020.1757441 (2020).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"17232_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41523-019-0112-z","volume":"5","author":"S Piawah","year":"2019","unstructured":"Piawah, S. et al. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer 5, 17. https:\/\/doi.org\/10.1038\/s41523-019-0112-z (2019).","journal-title":"NPJ Breast Cancer"},{"key":"17232_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40290-023-00489-5","volume":"37","author":"GA Toyserkani","year":"2023","unstructured":"Toyserkani, G. A., Lee, J. H. & Zhou, E. H. The risk evaluation and mitigation strategy (REMS) public dashboard: Improving transparency of regulatory activities. Pharmaceut. Med. 37, 349\u2013353. https:\/\/doi.org\/10.1007\/s40290-023-00489-5 (2023).","journal-title":"Pharmaceut. Med."},{"key":"17232_CR27","doi-asserted-by":"publisher","first-page":"6737062","DOI":"10.1155\/2023\/6737062","volume":"2023","author":"Y Su","year":"2023","unstructured":"Su, Y. et al. Exploring the effect of compound glycyrrhizin and silybinin on the metabolism of pexidartinib in rats based on cyp3a4 and cyp2c9. Adv. Pharmacol. Pharm. Sci. 2023, 6737062. https:\/\/doi.org\/10.1155\/2023\/6737062 (2023).","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"17232_CR28","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s40262-022-01172-9","volume":"61","author":"H Zahir","year":"2022","unstructured":"Zahir, H. et al. Evaluation of absorption and metabolism-based DDI potential of pexidartinib in healthy subjects. Clin. Pharmacokinet. 61, 1623\u20131639. https:\/\/doi.org\/10.1007\/s40262-022-01172-9 (2022).","journal-title":"Clin. Pharmacokinet."},{"key":"17232_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1021\/acs.chemrestox.3c00164","volume":"36","author":"X Qin","year":"2023","unstructured":"Qin, X. et al. Identifying the reactive metabolites of tyrosine kinase inhibitor pexidartinib in vitro using LC-MS-based metabolomic approaches. Chem. Res. Toxicol. 36, 1427\u20131438. https:\/\/doi.org\/10.1021\/acs.chemrestox.3c00164 (2023).","journal-title":"Chem. Res. Toxicol."},{"key":"17232_CR30","doi-asserted-by":"publisher","first-page":"114884","DOI":"10.1016\/j.ejmech.2022.114884","volume":"245","author":"J Wen","year":"2023","unstructured":"Wen, J., Wang, S., Guo, R. & Liu, D. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. Eur. J. Med. Chem. 245, 114884. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114884 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"17232_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s13023-023-02926-9","volume":"18","author":"C McCabe","year":"2023","unstructured":"McCabe, C., Wright, H., Polson, K. & Wagner, A. J. Supporting patients in the transition to the revised pexidartinib dosing regimen: Perspectives from the multidisciplinary clinical and allied health professional team. Orphanet. J. Rare Dis. 18, 313. https:\/\/doi.org\/10.1186\/s13023-023-02926-9 (2023).","journal-title":"Orphanet. J. Rare Dis."},{"key":"17232_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001153","author":"JP Machiels","year":"2020","unstructured":"Machiels, J. P. et al. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J. Immunother Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001153 (2020).","journal-title":"J. Immunother Cancer"},{"key":"17232_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004076","author":"C Gomez-Roca","year":"2022","unstructured":"Gomez-Roca, C. et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naive or experienced for immune checkpoint blockade. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-004076 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"17232_CR34","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-20-0855","volume":"26","author":"KA Autio","year":"2020","unstructured":"Autio, K. A. et al. Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A Phase I study. Clin. Cancer Res. 26, 5609\u20135620. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0855 (2020).","journal-title":"Clin. Cancer Res."},{"key":"17232_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35634","volume":"131","author":"J Desai","year":"2025","unstructured":"Desai, J. et al. A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib. Cancer 131, 35634. https:\/\/doi.org\/10.1002\/cncr.35634 (2025).","journal-title":"Cancer"},{"key":"17232_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OTT.S345878","volume":"15","author":"A Vaynrub","year":"2022","unstructured":"Vaynrub, A., Healey, J. H., Tap, W. & Vaynrub, M. Pexidartinib in the management of advanced tenosynovial giant cell tumor: Focus on patient selection and special considerations. Onco. Targets Ther. 15, 53\u201366. https:\/\/doi.org\/10.2147\/OTT.S345878 (2022).","journal-title":"Onco. Targets Ther."},{"key":"17232_CR37","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1007\/s00417-023-06350-4","volume":"262","author":"JA Oskam","year":"2024","unstructured":"Oskam, J. A. & Danesh-Meyer, H. V. Neuro-ophthalmic complications of modern anti-cancer drugs. Graefes Arch. Clin. Exp. Ophthalmol. 262, 2269\u20132281. https:\/\/doi.org\/10.1007\/s00417-023-06350-4 (2024).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"17232_CR38","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap, W. D. et al. Structure-guided blockade of csf1r kinase in tenosynovial giant-cell tumor. N Engl. J. Med. 373, 428\u2013437. https:\/\/doi.org\/10.1056\/NEJMoa1411366 (2015).","journal-title":"N Engl. J. Med."},{"key":"17232_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuron.2014.02.040","volume":"82","author":"MR Elmore","year":"2014","unstructured":"Elmore, M. R. et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380\u2013397. https:\/\/doi.org\/10.1016\/j.neuron.2014.02.040 (2014).","journal-title":"Neuron"},{"key":"17232_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108565","volume":"253","author":"MP Weyer","year":"2024","unstructured":"Weyer, M. P., Strehle, J., Schafer, M. K. E. & Tegeder, I. Repurposing of pexidartinib for microglia depletion and renewal. Pharmacol. Ther. 253, 108565. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108565 (2024).","journal-title":"Pharmacol. Ther."},{"key":"17232_CR41","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12974-023-02984-7","volume":"20","author":"SN Shaikh","year":"2023","unstructured":"Shaikh, S. N. et al. CSF-1R inhibitor PLX3397 attenuates peripheral and brain chronic GVHD and improves functional outcomes in mice. J. Neuroinflamm. 20, 300. https:\/\/doi.org\/10.1186\/s12974-023-02984-7 (2023).","journal-title":"J. Neuroinflamm."},{"key":"17232_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109436","volume":"113","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Pexidartinib (PLX3397) through restoring hippocampal synaptic plasticity ameliorates social isolation-induced mood disorders. Int. Immunopharmacol. 113, 109436. https:\/\/doi.org\/10.1016\/j.intimp.2022.109436 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"17232_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40478-014-0142-6","volume":"2","author":"WJ Streit","year":"2014","unstructured":"Streit, W. J., Xue, Q. S., Tischer, J. & Bechmann, I. Microglial pathology. Acta Neuropathol. Commun. 2, 142. https:\/\/doi.org\/10.1186\/s40478-014-0142-6 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"17232_CR44","doi-asserted-by":"publisher","first-page":"1305087","DOI":"10.3389\/fimmu.2024.1305087","volume":"15","author":"C Pallares-Moratalla","year":"2024","unstructured":"Pallares-Moratalla, C. & Bergers, G. The ins and outs of microglial cells in brain health and disease. Front. Immunol. 15, 1305087. https:\/\/doi.org\/10.3389\/fimmu.2024.1305087 (2024).","journal-title":"Front. Immunol."},{"key":"17232_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12017-023-08733-6","volume":"25","author":"S Tan","year":"2023","unstructured":"Tan, S. et al. CD33\/TREM2 signaling mediates sleep deprivation-induced memory impairment by regulating microglial phagocytosis. Neuromolecular. Med. 25, 255\u2013271. https:\/\/doi.org\/10.1007\/s12017-023-08733-6 (2023).","journal-title":"Neuromolecular. Med."},{"key":"17232_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110148","volume":"37","author":"M Puigdellivol","year":"2021","unstructured":"Puigdellivol, M. et al. The microglial P2Y(6) receptor mediates neuronal loss and memory deficits in neurodegeneration. Cell Rep. 37, 110148. https:\/\/doi.org\/10.1016\/j.celrep.2021.110148 (2021).","journal-title":"Cell Rep."},{"key":"17232_CR47","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1038\/s41467-023-42276-5","volume":"14","author":"Y Hasegawa","year":"2023","unstructured":"Hasegawa, Y. et al. Microglial cannabinoid receptor type 1 mediates social memory deficits in mice produced by adolescent THC exposure and 16p11.2 duplication. Nat. Commun. 14, 6559. https:\/\/doi.org\/10.1038\/s41467-023-42276-5 (2023).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17232-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17232-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17232-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:10:49Z","timestamp":1756354249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17232-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17232"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17232-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6283844\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants\u2019 legal guardians\/next of kin in accordance with the national legislation and the institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors utilized DeepSeek (\n                      \n                      ) for grammatical improvements in this manuscript. The authors take full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI statement"}}],"article-number":"31689"}}